

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

INTERLEUKIN GENETICS INC  
Form 8-K  
May 14, 2004

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 14, 2004

Interleukin Genetics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	000-23413	94-3123681
-----	-----	-----
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.) 94-3123681

135 Beaver Street, Waltham, MA 02452

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 398-0700

Not Applicable

(Former name or former address, if changed since last report)

Item 12. Disclosure of Results of Operations and Financial Condition.

The following exhibits are furnished with this report:

Exhibit Number	Description
-----	-----
99.1	Press Release dated May 14, 2004

On May 14, 2004, the Registrant issued a press release to report its

Edgar Filing: INTERLEUKIN GENETICS INC - Form 8-K

financial results for the quarter ended March 31, 2004. A copy of the press release is attached to this current report on Form 8-K as Exhibit 99.1.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Interleukin Genetics, Inc.

-----  
(Registrant)

Date: May 14, 2004

/s/ Fenel M. Eloi

-----  
Fenel M. Eloi  
Chief Operating Officer,  
Chief Financial Officer,  
Treasurer and Secretary

3